Complement inhibition in severe COVID-19 - Blocking C5a seems to be key.
作者信息
Lim Endry H T, Vlaar Alexander P J, de-Bruin Sanne, Brouwer Matthijs C, van-de-Beek Diederik
机构信息
Department of Intensive Care Medicine, Amsterdam University Medical Center, University of Amsterdam, Amsterdam UMC, 1100DD Amsterdam, the Netherlands.
Department of Neurology, Amsterdam Neuroscience, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, the Netherlands.
出版信息
EClinicalMedicine. 2021 Apr 24;35:100722. doi: 10.1016/j.eclinm.2021.100722. eCollection 2021 May.
Abstract
摘要
相似文献
1
Complement inhibition in severe COVID-19 - Blocking C5a seems to be key.重症 COVID-19 中的补体抑制——阻断 C5a 似乎是关键。
EClinicalMedicine. 2021 Apr 24;35:100722. doi: 10.1016/j.eclinm.2021.100722. eCollection 2021 May.
2
Complement inhibition in severe COVID-19 - Blocking C5a seems to be key: Author's reply.重症 COVID-19 中的补体抑制——阻断 C5a 似乎是关键：作者回复
EClinicalMedicine. 2021 May;35:100866. doi: 10.1016/j.eclinm.2021.100866. Epub 2021 Apr 25.
3
Inhibiting the C5-C5a receptor axis.抑制 C5-C5a 受体轴。
Mol Immunol. 2011 Aug;48(14):1631-42. doi: 10.1016/j.molimm.2011.04.014. Epub 2011 May 6.
4
Inhibition of C5a-induced inflammation with preserved C5b-9-mediated bactericidal activity in a human whole blood model of meningococcal sepsis.在人全血脑膜炎球菌败血症模型中抑制C5a诱导的炎症反应并保留C5b-9介导的杀菌活性。
Blood. 2003 Nov 15;102(10):3702-10. doi: 10.1182/blood-2003-03-0703. Epub 2003 Jul 24.
5
Targeting C5a: recent advances in drug discovery.靶向C5a：药物研发的最新进展
Curr Med Chem. 2005;12(2):217-36. doi: 10.2174/0929867053363379.
6
Critical role of C5a in sickle cell disease.C5a 在镰状细胞病中的关键作用。
Am J Hematol. 2019 Mar;94(3):327-337. doi: 10.1002/ajh.25384. Epub 2019 Jan 3.
7
8
Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKCζ.补体C5aR1信号通过蛋白激酶Cζ促进胚胎神经祖细胞的极化和增殖。
J Neurosci. 2017 May 31;37(22):5395-5407. doi: 10.1523/JNEUROSCI.0525-17.2017. Epub 2017 Apr 28.
9
Complement activation and endothelial perturbation parallel COVID-19 severity and activity.补体激活和内皮功能紊乱与 COVID-19 的严重程度和活动并行。
J Autoimmun. 2021 Jan;116:102560. doi: 10.1016/j.jaut.2020.102560. Epub 2020 Oct 29.
10
C5a receptor1 inhibition alleviates influenza virus-induced acute lung injury.C5a 受体 1 抑制减轻流感病毒诱导的急性肺损伤。
Int Immunopharmacol. 2018 Jun;59:12-20. doi: 10.1016/j.intimp.2018.03.029. Epub 2018 Apr 2.
引用本文的文献
1
Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill, invasively mechanically ventilated COVID-19 patients.在PANAMO中对vilobelimab、过敏毒素C5a和抗药物抗体进行的药代动力学分析：一项针对重症、有创机械通气的COVID-19患者的3期研究。
Intensive Care Med Exp. 2023 Jun 19;11(1):37. doi: 10.1186/s40635-023-00520-8.
2
Noninvasive nasopharyngeal proteomics of COVID-19 patient identify abnormalities related to complement and coagulation cascade and mucosal immune system.COVID-19 患者的无创性鼻咽蛋白质组学分析发现与补体和凝血级联以及黏膜免疫系统相关的异常。
PLoS One. 2022 Sep 12;17(9):e0274228. doi: 10.1371/journal.pone.0274228. eCollection 2022.
3
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.抗 C5a 抗体（vilobelimab）治疗 COVID-19 危重症、有创机械通气患者（PANAMO）：一项多中心、双盲、随机、安慰剂对照、3 期临床试验。
Lancet Respir Med. 2022 Dec;10(12):1137-1146. doi: 10.1016/S2213-2600(22)00297-1. Epub 2022 Sep 7.
4
Proteomic Profile of Procoagulant Extracellular Vesicles Reflects Complement System Activation and Platelet Hyperreactivity of Patients with Severe COVID-19.严重 COVID-19 患者促凝细胞外囊泡的蛋白质组学特征反映了补体系统激活和血小板高反应性。
Front Cell Infect Microbiol. 2022 Jul 22;12:926352. doi: 10.3389/fcimb.2022.926352. eCollection 2022.
5
α2,6-Sialylation is Upregulated in Severe COVID-19 Implicating the Complement Cascade.α2,6-唾液酸化在重症新型冠状病毒肺炎中上调，提示补体级联反应。
medRxiv. 2022 Jun 8:2022.06.06.22275981. doi: 10.1101/2022.06.06.22275981.
6
The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.抗 C5a 抗体 vilobelimab 可有效抑制重症 COVID-19 患者的 C5a。
Clin Transl Sci. 2022 Apr;15(4):854-858. doi: 10.1111/cts.13213. Epub 2022 Jan 14.
7
Complement inhibition in severe COVID-19 - Blocking C5a seems to be key: Author's reply.重症 COVID-19 中的补体抑制——阻断 C5a 似乎是关键：作者回复
EClinicalMedicine. 2021 May;35:100866. doi: 10.1016/j.eclinm.2021.100866. Epub 2021 Apr 25.
本文引用的文献
1
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study.依库珠单抗作为重症监护病房中成年重症 COVID-19 患者的紧急治疗：一项概念验证研究。
EClinicalMedicine. 2020 Nov;28:100590. doi: 10.1016/j.eclinm.2020.100590. Epub 2020 Nov 5.
2
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.抗C5a抗体IFX-1（vilobelimab）治疗与最佳支持治疗对重症COVID-19患者的疗效比较（PANAMO）：一项探索性、开放标签的2期随机对照试验。
Lancet Rheumatol. 2020 Dec;2(12):e764-e773. doi: 10.1016/S2665-9913(20)30341-6. Epub 2020 Sep 28.
3
Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis.补体和组织因子富集的中性粒细胞细胞外陷阱是 COVID-19 免疫血栓形成的关键驱动因素。
J Clin Invest. 2020 Nov 2;130(11):6151-6157. doi: 10.1172/JCI141374.
4
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.COVID-19 炎症与 C5a-C5aR1 轴的激活有关。
Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29.
5
Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition.控制疾病中的过敏毒素 C5a 需要有针对性的特异性抑制。
Clin Immunol. 2017 Jul;180:25-32. doi: 10.1016/j.clim.2017.03.012. Epub 2017 Mar 30.
Zotero 插件